Mr. Andre Larente reports

CORRECTION - DIAGNOS ANNOUNCES CLOSING OF PRIVATE PLACEMENT

Diagnos Inc. has corrected a news release. In the original press release dated Feb. 5, 2025, announcing the closing of a private placement of 6,715,370 units issued at a price of 30 cents per unit, for gross proceeds of $2,014,611; the number of units, the amount of gross proceeds and the amount of cash remuneration to finders were incorrect. The corrected news release is presented below. The company closed, on Feb. 5, 2025, a non-brokered private placement of 6,715,369 units issued at a price of 30 cents per unit, for gross proceeds of $2,014,610.70.

Each unit consists of:

• One common share;
• One common share warrant.

As part of the closing of the private placement, 6,715,369 warrants have been issued to the subscribers. Each warrant can be exercised, for a period of 18 months ending on Aug. 5, 2026, to purchase one share at a price of 40 cents per share.

In connection with the closing of the private placement, the corporation (i) paid cash commissions totalling $67,302.72 and (ii) issued an aggregate number of 130,821 finders' warrants to five qualified firms acting at arm's length to the corporation. Each finder's warrant entitles the holder to purchase one share at an exercise price of 40 cents per share for a period of 18 months ending on Aug. 5, 2026.

The net proceeds from the private placement will be used to finance product development and commercialization of artificial-intelligence-based screening services, regulatory affairs as well as general and administrative operations.

All securities issued as part of the private placement are subject to a statutory hold period ending June 6, 2025.

The closing of the private placement remains subject to receipt of all required approvals, including the approval of the TSX Venture Exchange, as well as execution of formal documentation.

All monies quoted in this press release shall be stated and paid in lawful money of Canada.

About Diagnos Inc.

Diagnos is a publicly traded Canadian corporation dedicated to early detection of critical health problems based on its Flaire artificial intelligence (AI) platform. Flaire allows for quick modifying and developing of applications such as CARA (computer-assisted retina analysis). CARA's image enhancement algorithms provide sharper, clearer and easier-to-analyze retinal images. CARA is a cost-effective tool for real-time screening of large volumes of patients.

We seek Safe Harbor.